EyePoint sinks on Duravyu phase 3 miss
· seekingalpha.com
EyePoint plunges 71% after Duravyu wet AMD phase 3 trial misses primary endpoint vs. Regeneron’s Eylea. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...